| 发明名称 |
TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND DINACICLIB |
| 摘要 |
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1. |
| 申请公布号 |
US2016193334(A1) |
申请公布日期 |
2016.07.07 |
| 申请号 |
US201414912771 |
申请日期 |
2014.08.15 |
| 申请人 |
MERCK SHARP & DOHME CORP. |
发明人 |
Strack Peter Richard;Booher Robert;Sriram Venkataraman;Phillips Joseph H. |
| 分类号 |
A61K39/395;A61K31/519 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a dinaciclib compound, wherein the dinaciclib compound is the compound of Formulaor a pharmaceutically acceptable salt of the compound of Formula I. |
| 地址 |
Rahway NJ US |
